TF and melanoma: The finding that TF-targeted therapies are able to eradicate CSCs, in addition to their direct effects on cancer cells and tumor vessels, may help explain the marked in vivo efficacy of ICON and fVII-tPDT, which can eradicate established tumor xenografts (100-500 mm3) and prevent recurrence in preclinical mouse models of human prostate [14], melanoma [17], tongue [21] and lung [15] cancer.